Stay updated with breaking news from Sight Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
Clinically meaningful difference between visual outcomes of LUMEVOQ®-treated patients and untreated patients Regulatory News: GenSight Biologics ...
Friday June 4th, 2021 8:00 am to 9:00 am EDT Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch - read this article along with other careers information, tips and advice on BioSpace
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of Françoise de Craecker to its Board of Directors, replacing Natalie Mount. Mrs. de Craecker is joining as an independent Director. “I am thrilled to be joining the GenSight team as they are transforming from an R&D company to a commercial organization with LUMEVOQ, their lead product for the treatment of LHON, being rev...